The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.
The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.
The conversation discusses a 5-month hair loss treatment regimen including finasteride, minoxidil, RU58841, dermapen (1.7mm), and ketoconazole shampoo, with noticeable hair regrowth. One user notes the hair appears thicker, while another mentions RU58841 is not doctor-recommended.
The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.
The user started shedding hair after beginning testosterone replacement therapy (TRT) despite using dutasteride and minoxidil, and added RU58841 to address the shedding. They reduced their TRT dose and hope RU58841 will stop the shedding quickly.
Alfatradiol is used as a mild treatment to slow or stabilize hair loss, often alongside finasteride and pumpkin seed oil. Users report reduced shedding and minimal side effects, but minoxidil is noted as more effective for regrowth.
Reducing the dose of RU58841 from 25mg to 7.5mg topically helped minimize heart palpitations. Users discussed the cardiac effects of RU58841 and minoxidil, noting that no treatment is completely free of side effects.
Hair loss treatments Finasteride, Dutasteride, Pyrilutamide, and RU58841 have different mechanisms of action. They can be used individually or stacked for better protection against hair loss.
The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
The user experienced severe hair shedding from RU58841 and recovered by stopping its use and starting treatments including Minoxidil, Rosemary Verbenone, Stemoxydine, Aminexil, copper peptide serum, and specific shampoos. They also consistently used oral Finasteride and plan to try Minoxidil 10%.
Tazarotene's potential to enhance Minoxidil conversion, similar to Tretinoin, is questioned. Users discuss the lack of information and seek further details.
A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.
A user's progress in hair regrowth after taking finasteride (1mg) every other day, and the replies to the post offering support, advice, and encouragement.
The user showed a one-year hair regrowth progress using finasteride only, after stopping minoxidil due to its toxicity to cats. They noticed hair growth around six or seven months into treatment.
ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.
Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.
The user has been on finasteride for 1.5 years with good results but avoids minoxidil due to pet safety concerns. They're considering alternatives like Redensyl and natural remedies like rosemary oil and stinging nettle tincture for hair loss.
The user started using 1mg oral finasteride a year ago and added oral minoxidil 3-4 months ago, experiencing no side effects except initial aching. They found oral minoxidil more effective for regrowth and easier than topical due to its toxicity to dogs.
A user's hair regrowth journey involved a hair transplant and using RU58841, finasteride, and minoxidil, with side effects managed by other medications.
There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.
Hair regrowth treatments are effective in mice but not yet available for humans. The discussion humorously highlights frustration over this disparity and mentions a project to genetically modify elephants to resemble mammoths.
PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.
User Solid_Repeat5382 shared their experience with Pyrilutamide for hair loss, which initially reduced shedding but later lost effectiveness. They plan to switch back to RU58841 and finasteride, while continuing minoxidil and dermapen treatments.
The conversation discusses concerns about the effectiveness of RU58841 due to high temperatures during delivery. A user reassures that the heat will not affect its efficacy.
A 25-year-old male experiencing hair shedding due to testosterone use is considering topical finasteride or RU58841 for scalp treatment while continuing minoxidil for beard growth. Topical finasteride is suggested to prevent scalp thinning without affecting beard growth.